SCHEMBL4200347

SCHEMBL4200347

O=c1c2cccnc2nc(-c2ccccc2F)n1NCc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
MDM2 Q00987 1/20 0.44
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43
F7 P08709 1/20 0.43
F3 P13726 1/20 0.43
IDO1 P14902 3/20 0.43
TP53 P04637 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EP300 Q09472 1/20 0.38
CREBBP Q92793 1/20 0.38
KAT2A Q92830 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202613 0.84 SMN1; SMN2 (0.48) ALDH1A1IDO1TP53CYP1A2CYP3A4
SCHEMBL4194113 0.80 DYRK1A (0.46) ALDH1A1IDO1CYP1A2CYP3A4CYP2D6
SCHEMBL4205026 0.78 IDO1 (0.42) ALDH1A1IDO1CYP1A2CYP3A4CYP2D6
SCHEMBL4238635 0.77 ALDH1A1 (0.47) ALDH1A1MDM2F7F3CYP1A2
SCHEMBL4241360 0.76 ALDH1A1 (0.62) ALDH1A1MDM2CYP1A2CYP3A4CYP2D6
SCHEMBL4191475 0.75 NPSR1 (0.57) ALDH1A1IDO1CYP1A2CYP3A4CYP2D6
SCHEMBL4233268 0.75 ALDH1A1 (0.58) ALDH1A1MDM2CYP1A2CYP3A4CYP2D6
SCHEMBL4239817 0.75 ALDH1A1 (0.61) ALDH1A1MDM2CYP1A2CYP3A4CYP2D6
SCHEMBL4200494 0.75 SMN1; SMN2 (0.48) IDO1TP53CYP1A2CYP3A4CYP2C9
SCHEMBL4241359 0.75 ALDH1A1 (0.58) ALDH1A1MDM2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 ALDH1A1 2426/4885MDM2 4742/4885F2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.